Optimal Central Venous Pressure During the Neohepatic Phase to Decrease Peak Portal Vein Flow Velocity for the Prevention of Portal Hyperperfusion in Patients Undergoing Living Donor Liver Transplantation

Maintaining CVP (approximately 8 mm Hg) during the neohepatic phase was clinically beneficial in decreasing PVV to prevent portal hyperperfusion in the early postoperative period of LDLT.